Accretion Pharmaceuticals Reports Robust Performance for FY26, Driven by Volume Expansion

Accretion Pharmaceuticals Reports Robust Performance for FY26, Driven by Volume Expansion​

Accretion Pharmaceuticals Limited, a key manufacturer of high-quality pharmaceutical formulations and contract development and manufacturing organization (CDMO) services, announced its audited financial results for the year ended March 31, 2026. The company reported robust growth, driven by volume expansion, an improved product mix, and an expanding global customer base.

The financial highlights confirm strong year-over-year growth across key metrics. For the fiscal year 2026 (FY26), the company reported a Net Revenue of Rs. 89.63 crore, marking a significant increase compared to the Rs. 57.38 crore recorded in FY25. Profit After Tax (PAT) also saw a substantial rise, increasing 42.30% YoY to Rs. 9.67 crore.

Financial Highlights Summary (Rs. In Crore)​

The following table outlines the key financial metrics for the company for the two most recent fiscal years:

Performance Drivers and Operational Updates​

Half-Year Performance (H2 FY26):
In the half year ended March 31, 2026, Net Revenue stood at Rs. 45.89 crore, growing 18.24% compared to Rs. 38.81 crore in H2 FY25. This growth was attributed to healthy volume growth and an improved product mix, supported by new customer additions and better utilization of capacities funded through an Initial Public Offering (IPO).

EBITDA (excluding other income) was recorded at Rs. 7.88 crore in H2 FY26, reflecting a 4.50% YoY increase from Rs. 7.54 crore in H2 FY25. The EBITDA margin for the half year was 17.17%. Profit After Tax (PAT) rose by 13.55% YoY to Rs. 4.92 crore.

Full-Year Performance (FY26):
For the full fiscal year 2026, Net Revenue reached Rs. 89.63 crore, demonstrating a strong YoY growth of 56.21% over FY25’s Rs. 57.38 crore. This annual growth was bolstered by strong volume expansion and an improved product mix, with the Oral Liquid and Tablet categories contributing significantly. Furthermore, the company noted an increase in its Export contribution, which stood at 8.56%.

EBITDA (excluding other income) for FY26 was Rs. 14.95 crore, marking a 25.85% increase from Rs. 11.88 crore in FY25. The Profit After Tax for the year was Rs. 9.67 crore, achieving a 42.30% YoY growth.

Management Commentary​

Mr. Vivek Ashok Kumar Patel, Promoter and Managing Director, stated that the strong financial and operational performance for FY26 was achieved through volume expansion and an improved product mix.

The company confirmed that its growth momentum was driven by its core export markets, supported by a healthy order book and an expanding product portfolio. Management emphasized that the focus during the year included scaling CDMO capabilities and improving capacity utilization across key dosage forms.

While noting that margins faced pressure from input costs, product mix changes, and initial investments in product registrations, the company expressed confidence in a gradual improvement in profitability as these investments began to yield returns and operating leverage increased. The export-led strategy remains a key growth driver, and the company is positioned to deepen its presence in existing regions while exploring new opportunities.

ACCPL Stock Price Movement​

Shares of Accretion Pharmaceuticals Limited are edging higher to ₹122.7 as of 3:10 PM today, gaining 1.07% in live trading. The stock has seen active movement, traversing a total volume of 13,200 shares.